NZ527720A - Synthetic vaccine agents - Google Patents

Synthetic vaccine agents

Info

Publication number
NZ527720A
NZ527720A NZ527720A NZ52772002A NZ527720A NZ 527720 A NZ527720 A NZ 527720A NZ 527720 A NZ527720 A NZ 527720A NZ 52772002 A NZ52772002 A NZ 52772002A NZ 527720 A NZ527720 A NZ 527720A
Authority
NZ
New Zealand
Prior art keywords
immunogen
poly
polyhydroxypolymer
epitope
immunogen according
Prior art date
Application number
NZ527720A
Other languages
English (en)
Inventor
Klaus Gregorius Nielsen
Peter Koefoed
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/DK2001/000113 external-priority patent/WO2001062284A2/en
Priority claimed from US09/785,215 external-priority patent/US7135181B2/en
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of NZ527720A publication Critical patent/NZ527720A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
NZ527720A 2001-02-19 2002-02-19 Synthetic vaccine agents NZ527720A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/DK2001/000113 WO2001062284A2 (en) 2000-02-21 2001-02-19 Novel method for down-regulation of amyloid
US09/785,215 US7135181B2 (en) 2000-02-21 2001-02-20 Method for down-regulation of amyloid
DKPA200101231 2001-08-20
US33754301P 2001-10-22 2001-10-22
PCT/DK2002/000112 WO2002066056A2 (en) 2001-02-19 2002-02-19 Synthetic vaccines comprising polyhydroxypolymer carriers

Publications (1)

Publication Number Publication Date
NZ527720A true NZ527720A (en) 2005-03-24

Family

ID=35160895

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ527720A NZ527720A (en) 2001-02-19 2002-02-19 Synthetic vaccine agents

Country Status (10)

Country Link
EP (1) EP1363664A2 (cg-RX-API-DMAC10.html)
JP (1) JP2004529881A (cg-RX-API-DMAC10.html)
CN (1) CN100562338C (cg-RX-API-DMAC10.html)
AU (1) AU2002233166B2 (cg-RX-API-DMAC10.html)
CA (1) CA2440197A1 (cg-RX-API-DMAC10.html)
IL (1) IL157475A0 (cg-RX-API-DMAC10.html)
NO (1) NO335602B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ527720A (cg-RX-API-DMAC10.html)
WO (1) WO2002066056A2 (cg-RX-API-DMAC10.html)
ZA (1) ZA200400895B (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024183A1 (en) * 2002-09-12 2004-03-25 Pharmexa A/S Immunization against autologous ghrelin
WO2005037190A2 (en) * 2003-09-03 2005-04-28 Dendritherapeutics, Inc. Multiplex vaccines
WO2005046605A2 (en) * 2003-11-07 2005-05-26 University Of Rochester Compositions and methods of treating neurological diseases
AU2012229234B2 (en) * 2011-03-11 2016-02-25 Flow Pharma Inc. Vaccine formulation of mannose coated peptide particles
CN103665113A (zh) * 2012-09-14 2014-03-26 深圳市安群生物工程有限公司 人Aβ42抗原决定簇多肽、抗原、抗体、用途及试剂盒
RU2635517C1 (ru) * 2016-09-14 2017-11-13 Закрытое акционерное общество "Институт фармацевтических технологий" (ЗАО "ИФТ") Синтетический иммуноген для защиты и лечения от зависимости от психоактивных веществ
CN112165956A (zh) * 2018-04-10 2021-01-01 Ac免疫有限公司 抗Aβ治疗性疫苗
MA52180A (fr) 2018-04-10 2021-02-17 Ac Immune Sa Vaccins thérapeutiques anti-abêta

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0625910B1 (en) * 1992-02-11 2003-07-23 Henry M. Jackson Foundation For The Advancement Of Military Medicine Dual carrier immunogenic construct
AU4377793A (en) * 1992-05-20 1993-12-13 Johns Hopkins University, The Alternative receptor therapy
KR100731820B1 (ko) * 1998-10-05 2007-06-25 파멕사 에이/에스 치료적 백신화를 위한 새로운 방법

Also Published As

Publication number Publication date
JP2004529881A (ja) 2004-09-30
ZA200400895B (en) 2005-05-03
CN100562338C (zh) 2009-11-25
AU2002233166B2 (en) 2006-06-29
CA2440197A1 (en) 2002-08-29
WO2002066056A2 (en) 2002-08-29
CN1893970A (zh) 2007-01-10
IL157475A0 (en) 2004-03-28
NO335602B1 (no) 2015-01-12
NO20040431L (no) 2004-04-16
WO2002066056A8 (en) 2004-04-29
EP1363664A2 (en) 2003-11-26
WO2002066056A3 (en) 2003-01-03

Similar Documents

Publication Publication Date Title
US7097837B2 (en) Synthetic vaccine agents
JP4087898B2 (ja) 免疫原性に乏しい抗原と合成ペプチド担体との結合体およびそれらからなるワクチン
RS51699B (sr) Beta-amiloid-analog-t-ćelijski-epitop vakcina
CA2379852A1 (en) Method for down-regulating gdf-8 activity
EP3986447A1 (en) Rationally engineered carrier proteins for vaccines
US20040191264A1 (en) Synthetic vaccine agents
JPH0832637B2 (ja) 合成免疫原
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
WO2002034287A2 (en) Therapeutic vaccine formulations containing chitosan
US20030049253A1 (en) Polymeric conjugates for delivery of MHC-recognized epitopes via peptide vaccines
US20050063952A1 (en) Immunogenic CEA
US20020172673A1 (en) Method for down-regulating IgE
JP2005528373A (ja) 免疫プロトコルにFlt3リガンドを用いる方法
AU2002233166A1 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
US20040037840A1 (en) Novel therapeutic vaccine formulations
EP1539232A1 (en) Immunization against autologous ghrelin
CN101448517A (zh) 用于疾病免疫干预的单价和多价合成多糖抗原
US20080253993A1 (en) Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
US20200289629A1 (en) Toxoplasma gondii vaccines and their use
JP2022544407A (ja) 免疫原性組成物
US20220332770A1 (en) High-Density Flagellin-Displaying Virus-Like Particle As Vaccine Carrier
EP4701655A1 (en) Tp0751 chimera-containing vaccine
RS49960B (sr) Postupak za regulisanje smanjenja aktivnosti osteoprotegerinskog liganda
HK1130687A (en) Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)